# OnCo record litespark-012 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/litespark-012/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "litespark-012", "NCT04736706" ;
  schema:name "LITESPARK-012"@en ;
  schema:description "Adding belzutifan to first-line lenvatinib-pembrolizumab did not deliver, a reminder that later-line success does not guarantee first-line benefit."@en ;
  schema:url <https://onco.cc/trials/litespark-012/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04736706>, <https://www.curetoday.com/view/litespark-012-trial-falls-short-in-advanced-kidney-cancer> ;
  onco:status "negative" ;
  onco:tag "lesson:first-line-intensification" ;
  onco:phase "3" ;
  schema:startDate "2021-04-14" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> .